These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14581143)

  • 1. Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats.
    Oya M; Hosokawa M; Tsukada H; Fukuda K; Nakamura H; Tsukiyama K; Nagashima K; Fujimoto S; Yamada Y; Seino Y
    Diabetes Res Clin Pract; 2003 Nov; 62(2):69-77. PubMed ID: 14581143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
    Isogai S; Inokuchi T; Ohe K
    Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
    Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
    J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K; Sato N; Sato K; Shimizu H; Mori M
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epalrestat prevents the decrease in gastric mucosal blood flow and protects the gastric mucosa in streptozotocin diabetic rats.
    Suzuki H; Shimosegawa T; Ohara S; Toyota T
    J Gastroenterol; 1999 Apr; 34(2):172-7. PubMed ID: 10213114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
    Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
    Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an aldose reductase inhibitor on altered sympathetic nerve responsiveness of isolated right atria in diabetic rats.
    Sato N; Hashimoto H; Takiguchi Y; Nakashima M
    Arzneimittelforschung; 1990 Jul; 40(7):763-6. PubMed ID: 2121149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
    Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
    Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state.
    Nakano I; Tsugawa T; Shinohara R; Watanabe F; Fujita T; Nagata M; Kato T; Himeno Y; Kobayashi T; Fujiwara K; Nagata M; Itoh M; Nagasaka A
    J Diabetes Complications; 2003; 17(6):337-42. PubMed ID: 14583178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.
    Yang BB; Hong ZW; Zhang Z; Yu W; Song T; Zhu LL; Jiang HS; Chen GT; Chen Y; Dai YT
    Int J Impot Res; 2019 Mar; 31(2):97-104. PubMed ID: 30214006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aldose reductase inhibition with epalrestat on diabetes-induced changes in rat isolated atria.
    Booth RJ; Hodgson WC
    Clin Exp Pharmacol Physiol; 1993 Apr; 20(4):207-13. PubMed ID: 8485921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
    Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
    Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
    Kanda M; Eto K; Tanabe N; Sugiyama A; Hashimoto K; Ueno A
    Jpn J Pharmacol; 1997 Mar; 73(3):221-8. PubMed ID: 9127817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats.
    Tong YC; Cheng JT
    J Urol; 2007 Nov; 178(5):2203-7. PubMed ID: 17870109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
    Asano T; Saito Y; Kawakami M; Yamada N;
    J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
    Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
    Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.